RAC

2.20%

$1.78 race oncology ltd

See mason this is the misleading info you post to try and push...

First 675 Last

Share
Profile

Follow
Bluegumnuts

6,972 Posts.

866

20/07/24

06:18

Post #: 74837357
Share

Originally posted by Mason14: ↑

It's really not that hard to find for someone of adequate skill.

Below is a systematic review of oncolytic viruses from 2020, which includes 86 clinical trials - 60, of which, are phase 1. Gee, I wonder why there aren't many P2s relative to P1s. Imagine doubling and tripling down on a product joining a loooong list of failures when you could have made bank like management and Fong did.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589713/

There have been 8 phase II trials investigating Bisantrene as a single agent at a 250 mg/m2 7-day regimen, with an average weighted CR rate of 50.7%. I've attached the 7 PDFs that are available with the other paper quoted in three of the papers.

Spadea 1993_P2 Bisantrene in relapsed refractory AML.pdf
Canaai 2020_P2 AML.pdf
Bezwoda 1989_Bisantrene in ANLL.pdf
Fenaux 1991_P2 Bisantrene as salvage Tx.pdf
Isnard 1987_P2 bisantrene in relapsing or refractory leukemia.pdf
Marty 1984_Bisantrene P2 in ANLL0001.pdf
Tosi 1989_P2 bisantrene in ANLL.pdf

Here is how that data compares to approved therapies in the same patient populations. Note: Bisantrene is a first-in-class CPACS drug that modulates m6A levels through the inhibition of FTO, which is also a first-in-class. The clinical competitors are 0 as are the commercial competitors.

Here is a P1 trial of Bisantrene that you should probably look at. Have you ever thought you don't understand Bisantrene because you don't know what good looks like? 35% ORR in this P1 is the same response rate quoted on the FDA label for Doxorubicin

Marty 1985_ANLL (AML) P1.pdf

Now, show me a cardioprotective anti-cancer agent.

Expand

See mason this is the misleading info you post to try and push your narrative you get caught out on over and over again on the other thread…. You are trying to use data from different phases to say look it is showing a worse ORR is pure misleading information as you simply don’t know what dosing levels they will achieve as phase 1 is just about safety

Anyway enough about your misleading postings about the other one!!

I will go through the Bisantree papers after my coffee

RAC Price at posting: $1.83 Sentiment: None Disclosure: Not Held
2 Upvote

0 Great analysis

Reply

Top Stories

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

KAL

KalGold rolls out detailed aeromagnetic survey across Pinjin project

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

The winners & losers on market if negative gearing were gone

The market's shrugged at China's stimulus measures all year. Why is this one different?

NAM

ACCC seeks Olam divestments before it can buy Namoi Cotton

There are more pages in this discussion • 231 more messages in this thread...

First 675 Last

Add RAC (ASX) to my watchlist

(20min delay)
Last $1.78		Change -0.040(2.20%)		Mkt cap ! $302.5M

Open	High	Low	Value	Volume
$1.81	$1.82	$1.76	$132.8K	74.40K

Buyers (Bids)

No.	Vol.	Price($)
1	170	$1.77

Sellers (Offers)

Price($)	Vol.	No.
$1.78	2	1

View Market Depth

No.	Vol.	Price($)
2	4000	1.755
3	12714	1.750
1	3000	1.740
1	1405	1.720
4	25414	1.700

Price($)	Vol.	No.
1.780	3781	1
1.830	7500	1
1.840	1000	1
1.850	5222	1
1.880	2351	1

Last trade - 16.10pm 27/09/2024 (20 minute delay)

RAC (ASX) Chart

See mason this is the misleading info you post to try and push...

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

KalGold rolls out detailed aeromagnetic survey across Pinjin project

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

The winners & losers on market if negative gearing were gone

The market's shrugged at China's stimulus measures all year. Why is this one different?

ACCC seeks Olam divestments before it can buy Namoi Cotton

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

See mason this is the misleading info you post to try and push...

Top Stories

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

KalGold rolls out detailed aeromagnetic survey across Pinjin project

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

The winners & losers on market if negative gearing were gone

The market's shrugged at China's stimulus measures all year. Why is this one different?

ACCC seeks Olam divestments before it can buy Namoi Cotton

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News